This real-life approach allowed for the inclusion of a broad spectrum of clinical scenarios, providing a realistic assessment of the impact of metformin and hyperprolactinemia on galectin-3 levels in women with PCOS. This evidence concerns the gene LGALS3 and polycystic ovary syndrome.